Key result
Tricuspid valve replacement after cardiac transplantation significantly reduced furosemide dose (105 vs 67.5 mg/d, p=0.001) and improved albumin and bilirubin levels at 6 months.
Why the study?
Does tricuspid valve replacement improve clinical and laboratory parameters in post-cardiac transplant patients?
Population
9 patients who underwent tricuspid valve replacement after cardiac transplantation, mean age 62 +/- 6.1…
Comparison
Tricuspid valve replacement (TVR) vs Pre-TVR baseline (intra-patient comparison)
Design
Case_series
Follow-up
6 months
Authors
Loading...
May support TVR in selected post-transplant patients; leaves open confirmation in prospective studies.
Observational (n=9)
Does tricuspid valve replacement improve clinical and laboratory parameters in post-cardiac transplant patients?
Absolute Event Rate: 67.5% vs 105%
p-value: p=0.001
Tricuspid valve replacement appears safe and may improve nutritional status and reduce diuretic requirements in selected post-cardiac transplant patients without severe graft atherosclerosis.
Raghavan et al. (2006) conducted an observational in Tricuspid regurgitation after cardiac transplantation (n=9). Tricuspid valve replacement vs. Pre-intervention baseline was evaluated on Furosemide dose (mg/d) (p=0.001). Tricuspid valve replacement after cardiac transplantation significantly reduced furosemide dose (105 vs 67.5 mg/d, p=0.001) and improved albumin and bilirubin levels at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: